Drug Profile
Research programme: drug discovery - Argenta/Genentech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genentech
- Developer Argenta; Genentech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom
- 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories